ABIVAX vs Bausch + Lomb

ABIVAX (ABVX), health care, and Bausch + Lomb (BLCO), health care, side by side on market value, valuation, margins, balance sheet and price change. Higher and lower are marked; neither is called better.

Bausch + Lomb is worth $7.4B on the stock market and ABIVAX $7.2B: Bausch + Lomb is valued at 4% more. Over the past year ABIVAX's share price has moved -26.5% and Bausch + Lomb's +38.3%.

Key facts

ABIVAX market value
$7.2B
Bausch + Lomb market value
$7.4B
Bausch + Lomb revenue
$5.1BFY to 2025-12-31
Superinvestors holding both
0

Market values as of .

ABIVAX vs Bausch + Lomb: every measure side by side
Measure ABIVAX Bausch + Lomb
SectorHealth CareHealth Care
Country France Canada
Fiscal year ends2025-12-312025-12-31
Size
Market cap$7.2Blower$7.4Bhigher
Revenue—$5.1B
Earnings-$372.9Mlower-$360Mhigher
Employees98lower13,000higher
Total assets$648.3Mlower$14Bhigher
Valuation
P/E——
P/S—1.5
P/B——
Dividend yield——
Profitability
Operating margin—2.22%
Balance sheet
Net assets$505.1Mlower$6.4Bhigher
Total liabilities$143.3Mlower$7.5Bhigher
Total debt—$5B
Cash on hand$573.3Mhigher$383Mlower
Price change
Today-1.81%lower-0.24%higher
1 year-26.5%lower+38.3%higher

Market value, P/E, P/B, dividend yield and price changes are from live quotes (Yahoo Finance; prices may be delayed 15 minutes or more). Revenue, earnings, operating margin and the balance-sheet figures are from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day. P/S sets today's market value against the latest fiscal year's revenue. “Higher” and “lower” compare the two numbers only; a higher P/E or more debt is not better. Dividend yield and P/B are shown only for companies based in the US. A dash means no figure is on file.

Loading the one-year price chart…

Which superinvestors hold them

From each tracked investor's latest 13F filing. A 13F lists long positions in US-listed shares at a quarter end, filed up to 45 days later.

Both (0)

None of the tracked investors.

Bausch + Lomb only (4)

Percentages are each holding's share of that investor's reported portfolio. Who owns ABVX · Who owns BLCO

Further comparisons

Learn

Questions and answers

Which is bigger, ABIVAX or Bausch + Lomb?

By market value, Bausch + Lomb is the larger: $7.4B against $7.2B for ABIVAX.

Which superinvestors own both ABIVAX and Bausch + Lomb?

None of the tracked superinvestors holds both in their latest 13F filing. 4 hold ABIVAX and 4 hold Bausch + Lomb.

Cite this page

Funkfolio, “ABIVAX vs Bausch + Lomb”, data as of 17 November 2026. https://funkfolio.com/compare/abvx-vs-blco

Underlying data: Yahoo Finance quotes; SEC annual reports collected 2026-11-12; 13F filings.